Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.
J Gen Virol. 1996 Mar;77 ( Pt 3):419-26. Unique Identifier : AIDSLINE MED/96177321 Borman AM; Paulous S; Clavel F; Unite d'Oncologie Virale and CNRS URA 1157, Departement Sida et; Retrovirus, Institut Pasteur, 75724 Paris, France.
Abstract:
Inhibitors of the human immunodeficiency virus (HIV) protease are a promising class of antiviral agents that dramatically reduce HIV replication both in culture and in infected patients. However, as for many other antiviral compounds, long-term efficacy of these agents is impeded by the emergence of virus variants with increased resistance to their inhibitory action, following selection of specific mutations in the protease coding sequence. We have studied HIV-1 variants that emerged at different stages of selection in the presence of the C2-symmetrical protease inhibitor ABT-77003. The selection of variants was a gradual process during which mutations accumulated at different sites in the protease, generating virus populations with increasing levels of resistance to the drug. The initially selected viruses had a low level of resistance as well as a markedly reduced replicative capacity. Further accumulation of mutations at secondary sites led to an improvement in both drug resistance and replication. In spite of their reduced infectivity, partially selected virus populations did not readily revert to wild-type when serially passaged in drug-free conditions. Instead, even in the absence of drug, secondary mutations identical to those selected in the presence of the inhibitor continued to emerge. These mutations improved both the intrinsic replicative capacity of the virus and its level of resistance to the inhibitor, suggesting that once committed to drug resistance, readaptation of the enzyme to its natural substrate leads to a reduction of its sensitivity to the inhibitor.
Keywords: Amino Acid Sequence Antiviral Agents/*PHARMACOLOGY Base Sequence Drug Resistance, Microbial/GENETICS DNA Primers Hela Cells Human HIV Protease Inhibitors/*PHARMACOLOGY HIV-1/*DRUG EFFECTS/ENZYMOLOGY/GENETICS Methylurea Compounds/*PHARMACOLOGY Molecular Sequence Data *Mutation Pyridines/*PHARMACOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLE 960730
M9670448
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
